The enzyme contributes to the synthesis of estrogen precursors, and interventions targeting CYP17A1 have been explored to mitigate estrogen production and dampen the stimulatory effects on breast cancer cells [18,22,27]. This evidence concerns the gene CYP17A1 and breast carcinoma.